The Goldman Sachs Group Increases Autolus Therapeutics (NASDAQ:AUTL) Price Target to $4.80

Autolus Therapeutics (NASDAQ:AUTL – Free Report) had its price target increased by The Goldman Sachs Group from $3.20 to $4.80 in a report issued on Wednesday, Benzinga reports. The firm currently has a neutral rating on the stock. Other research analysts have also issued research reports about the stock. Deutsche Bank Aktiengesellschaft started coverage on […]

Related Keywords

William Blair ,Goldman Sachs Group ,Alyeska Investment Group ,Needham Company ,Nantahala Capital Management ,Autolus Therapeutics Company Profile ,Affinity Asset Advisors ,Deutsche Bank Aktiengesellschaft ,Autolus Therapeutics ,Free Report ,Bank Aktiengesellschaft ,Moderate Buy ,Get Free Report ,Capital Management ,Asset Advisors ,Autolus Therapeutics Daily ,Nasdaq Autl ,Autl ,Medical ,Boost Price Target ,The Goldman Sachs Group Inc ,